Amyloid Neuropathies Market

Market Overview:

The 7 major amyloid neuropathies markets are expected to exhibit a CAGR of 4.8% during 2024-2034.

The amyloid neuropathies market has been comprehensively analyzed in IMARC's new report titled "Amyloid Neuropathies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Amyloid neuropathies are a group of neurological disorders characterized by the deposition of irregular protein aggregates, called amyloid, within peripheral nerves. This disease can lead to nerve damage and dysfunction, resulting in a range of debilitating symptoms. Common indications of the ailment include sensory disturbances, such as tingling, numbness, and burning sensations in the extremities, muscle weakness, and impaired coordination. Pain, especially in the limbs, and autonomic dysfunction, manifesting as changes in blood pressure, heart rate, and digestion, are also frequent features. The diagnosis of amyloid neuropathies typically involves a combination of clinical assessment, nerve conduction studies, and nerve biopsies. The identification of amyloid deposits within nerve tissue through a biopsy is crucial for confirming the diagnosis. Additionally, advanced imaging techniques like MRI can aid in evaluating nerve damage and the distribution of amyloid deposits. Distinguishing the specific type of amyloid involved is essential, as treatment approaches may vary depending on the underlying cause.

The escalating incidences of genetic mutations that cause the protein to misfold and aggregate into amyloid deposits, which accumulate in various tissues, including nerves, are primarily driving the amyloid neuropathies market. In addition to this, the inflating utilization of efficacious treatments like monoclonal antibodies, proteostasis modulators, and gene-silencing therapies aimed at mitigating symptoms and halting disease progression is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive therapies, such as pain management strategies, physical rehabilitation, and targeted interventions to address specific indications associated with the condition, is further bolstering the market growth. Apart from this, the rising usage of novel technologies like RNA interference, which enables the selective suppression of the genes responsible for abnormal protein production, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of physical and rehabilitative therapies, since they are designed to improve muscle strength, balance, and functional autonomy, is also augmenting the market growth. Furthermore, the increasing R&D activities to launch novel therapies like antisense oligonucleotides that target the underlying genetic mechanisms, thereby offering potential curative interventions with greater efficacy and reduced side effects, are expected to drive the amyloid neuropathies market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the amyloid neuropathies market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for amyloid neuropathies and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the amyloid neuropathies market in any manner.

Recent Developments:

• In March 2024, Intellia Therapeutics announced the first patient dosage in the global pivotal Phase 3 MAGNITUDE study of NTLA-2001. NTLA-2001 is an experimental in vivo CRISPR-based therapy proposed as a single-dose treatment to inactivate the TTR gene and thereby prevent TTR protein production in the treatment of transthyretin (ATTR) amyloidosis. The MAGNITUDE trial is testing the efficacy and safety of NTLA-2001 in patients with ATTR amyloidosis and cardiomyopathy.
• In December 2023, Ionis Pharmaceuticals stated that the United States FDA had approved Ionis and AstraZeneca's eplontersen for the treatment of hereditary transthyretin-mediated amyloidosis in adults, also known as hATTR-PN or ATTRv-PN. Eplontersen is the only approved drug for ATTRv-PN that can be self-administered with an auto-injector.

Key Highlights:

• AL amyloidosis is the most frequent type of amyloidosis in the United States, with one instance per 100,000 person-years in Western countries.
• In the United States, there are around 1,275-3,200 new instances each year, with males being more likely to be affected.
• Patients with AL amyloidosis develop peripheral neuropathy in 17-35% of cases, and the usual period from diagnosis to death is 25-35 months.
• The mid-global prevalence of ATTRv is estimated at 1/450,000 persons.
• Congestive heart failure and renal failure are frequently the causes of death.

Drugs:

Amvuttra (Vutrisiran) is an RNAi therapy for treating polyneuropathy of hereditary transthyretin-mediated amyloidosis in adult patients. AMVUTTRA utilizes the body's natural silencing complex to reduce the synthesis of the disease-causing protein.

Eplontersen is a ligand-conjugated antisense (LICA) drug that inhibits the formation of transthyretin, or TTR protein. Eplontersen injection for subcutaneous usage 45 mg is intended for treating the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

NTLA-2001 is the first investigational CRISPR therapy delivered systemically to modify genes within the human body. NTLA-2001 has the potential to be the first single-use treatment for transthyretin amyloidosis. NTLA-2001 is intended to inactivate the TTR gene, which codes for the transthyretin (TTR) protein.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the amyloid neuropathies market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the amyloid neuropathies market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current amyloid neuropathies marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the amyloid neuropathies market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the amyloid neuropathies market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the amyloid neuropathies market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of amyloid neuropathies across the seven major markets?
• What is the number of prevalent cases (2018-2034) of amyloid neuropathies by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of amyloid neuropathies by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with amyloid neuropathies across the seven major markets?
• What is the size of the amyloid neuropathies patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of amyloid neuropathies?
• What will be the growth rate of patients across the seven major markets?
   

Amyloid Neuropathies: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for amyloid neuropathies drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the amyloid neuropathies market?
• What are the key regulatory events related to the amyloid neuropathies market?
• What is the structure of clinical trial landscape by status related to the amyloid neuropathies market?
• What is the structure of clinical trial landscape by phase related to the amyloid neuropathies market?
• What is the structure of clinical trial landscape by route of administration related to the amyloid neuropathies market?